Cancer treatment turbocharges patients' own blood cells to kill solid tumours for first time
A LIVING cancer drug has been proven to work against solid tumours for the first time.
Immune-boosting CAR-T therapy removes a patient's white blood cells and engineers them into highly specialised cancer killers in a lab.
1
They are then injected back into the patient and let loose against the disease.
It is currently only used for blood cell cancers like leukaemia but research by Peking University in China has found it can also work against tumours that form as lumps.
In a study of 266 people with stomach cancer, patients who received the treatment survived an average of 7.9 months compared to 5.5 months without it.
It took 3.3 months for their cancer to worsen, compared to 1.8 months without.
Study author Dr Changsong Qi said the results showed a 'significant increase in progression-free survival and clinically meaningful increase in overall survival'.
More than 90 per cent of cancers are solid tumours that grow as a physical mass, including the big four of bowel, breast, lung and prostate.
The findings raise the hope that tens or even hundreds of thousands more patients will one day benefit from the pioneering approach using their own immune systems instead of harsh drugs.
'Groundbreaking milestone'
Dr Carl June, of the University of Pennsylvania, is credited with inventing the therapy and commented: 'This is a groundbreaking milestone for the field of CAR-T therapies against solid tumours.'
CAR-T therapy, full name chimeric antigen receptor T-cell therapy, is an advanced type of immunotherapy that turbocharges the body's own defences to fight off cancer.
It is intended to be more accurate and cause less collateral damage and side effects by only attacking cancerous cells and not healthy ones.
Sun Health Explainer: What is cancer?
Young Sunderland fan Bradley Lowery took part in a major clinical trial of it in 2017 before dying from neuroblastoma aged six.
It is currently available on the NHS in England for certain types of leukaemia and lymphoma.
More than 650 forms of the treatment are now in development for solid cancers.
Dr John Haanen, from the Netherlands Cancer Institute, said: 'There is clearly now evidence that this treatment can benefit patients with solid cancers. It is an important development.'
The study was published in The Lancet and presented at the conference of the American Society for Clinical Oncology.
Dr Catherine Elliott, of Cancer Research UK, said: 'This is an encouraging early sign and further trials will now be needed.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
33 minutes ago
- Reuters
OECD trims global outlook as Trump trade war hits U.S. growth
PARIS, June 3 (Reuters) - Global economic growth is slowing more than expected only a few months ago as the fallout from the Trump administration's trade war takes a bigger toll on the U.S. economy, the OECD said on Tuesday, revising down its outlook. The global economy is on course to slow from 3.3% last year to 2.9% in 2025 and 2026, the Organisation for Economic Cooperation and Development said, trimming its estimates from March for growth of 3.1% this year and 3.0% next year. But the growth outlook would likely be even weaker if protectionism increases, further fuelling inflation, disrupting supply chains and rattling financial markets, the Paris-based organisation said in its latest Economic Outlook. U.S. President Donald Trump's tariff announcements since he took office in January have already roiled financial markets and fuelled global economic uncertainty, forcing him to walk back some of his initial stances. Last month, the U.S. and China agreed to a temporary truce to scale back tariffs, while Trump also postponed 50% duties on the European Union until July 9. The OECD forecast the U.S. economy would grow only 1.6% this year and 1.5% next year, assuming for the purpose of making calculations that tariffs in place mid-May would remain so through the rest of 2025 and 2026. For 2025, the new forecast marked a sizeable cut as the organisation had previously expected the world's biggest economy would grow 2.2% this year and 1.6% next year. While new tariffs may create incentives to manufacture in the United States, higher import prices would squeeze consumers' purchasing power and economic policy uncertainty would hold back corporate investment, the OECD warned. Meanwhile, the higher tariff receipts would only partly offset revenues lost due to the extension of the 2017 Tax Cuts and Jobs Act, new tax cuts and weaker economic growth, it added. Trump's sweeping tax cut and spending bill was expected to push the U.S. budget deficit to 8% of economic output by 2026, among the biggest fiscal shortfalls for a developed economy not at war. As tariffs fuel inflation pressures, the Federal Reserve was seen keeping rates on hold through this year and then cutting the fed funds rate to 3.25-3.5% by the end of 2026. In China, the fallout from the U.S. tariff hikes would be partly offset by government subsidies for a trade-in programme on consumer goods like mobile phones and appliances and increased welfare transfers, the OECD said. It estimated the world's second-biggest economy, which is not an OECD member, would grow 4.7% this year and 4.3% in 2026, little changed from previous forecasts for 4.8% in 2025 and 4.4% in 2026. The outlook for the euro area was unchanged from March with growth forecast this year at 1.0% and 1.2% next year, boosted by resilient labour markets and interest rate cuts while more public spending from Germany would buoy 2026 growth. The UK outlook was a tad better than in March with growth forecast at 1.3% this year and 1.0% in 2026, revised marginally lower from March estimates for 1.4% in 2025 and 1.2% in 2026.
Reuters
an hour ago
- Reuters
Two Japanese men killed in northeast China after business dispute
TOKYO/BEIJING June 3 (Reuters) - China's Foreign Ministry said on Tuesday that two Japanese men killed last month in the northeastern city of Dalian were business partners of the suspect and authorities were investigating. Dalian police confirmed the case in a statement on Tuesday and said a 42-year-old male suspect of Chinese nationality has been arrested. He had lived in Japan for a long time, the statement said. The two victims were business partners of the suspect who had entered China temporarily, police said, adding that the incident was triggered due to business conflicts. Kyodo News had reported the incident earlier on Tuesday, citing the Japanese embassy in China. Chinese police notified the Japanese consulate in Shenyang on May 25 about the killings, the report said.
Reuters
an hour ago
- Reuters
Hong Kong leader says sudden removal of China's top official in the city was "normal"
HONG KONG, June 3 (Reuters) - Hong Kong's leader said on Tuesday that China's recent removal of its top representative in the city, known for his hardline policies on national security, had been a "normal" personnel change. In a surprise development, China announced late on Friday that Zheng Yanxiong, the director of China's Liaison Office in Hong Kong - Beijing's main representative office in the city with powerful oversight over local affairs - had been "removed" from his post. He was replaced by Zhou Ji, a senior official with the Hong Kong and Macau Affairs Office on the State Council. Zheng, who played a key role in the crackdown on Hong Kong's democratic movement in recent years, was also stripped of his role as China's national security adviser on a committee overseeing national security in Hong Kong. No explanation by Beijing or Chinese state media was given for the change. According to a person with knowledge of the matter, Hong Kong-based conglomerate CK Hutchison's ( opens new tab proposed sale of its global port network to a consortium initially led by U.S. firm Blackrock had caught senior Chinese leaders "by surprise" as they had not been informed beforehand and Zheng was partly blamed for that. The person, who has spoken with the liaison office, declined to be identified as the discussions were confidential. The Liaison Office gave no immediate response to faxed questions from Reuters. Zheng had served in the post since January 2023 and while the position has no fixed term, his tenure was shorter than predecessors including Luo Huining and Zhang Xiaoming. "The change of the Liaison office director is I believe, as with all changes of officials, very normal," Lee told reporters during a weekly briefing, without being drawn on reasons for the reshuffle. "Director Zheng has spent around 5 years (in Hong Kong). Hong Kong was going through a transition period of chaos to order," Lee said, referring to the months-long pro-democracy protests that erupted across Hong Kong in 2019 while adding that he looked forward to working with Zhou. CK Hutchison's ports deal has been criticised in Chinese state media as "betraying" China's interests and bowing to U.S. political pressure. The conglomerate, controlled by tycoon Li Ka-shing, agreed in March to sell the majority of its $22.8 billion global ports business, including assets along the strategically significant Panama Canal, to the consortium. The consortium is now being led by another member - Terminal Investment Limited, which is majority-owned by Italian billionaire Gianluigi Aponte's family-run MSC Mediterranean Shipping Company. The deal is still being negotiated. Asked whether Zheng's removal reflected a pivot by Beijing towards economic development from national security, Lee said Hong Kong still needed to pursue both. "Hong Kong faces a stage where development and safety must be addressed at the same time because any development must have a safe environment." China promulgated a powerful national security law in 2020, arresting scores of opposition democrats and activists, shuttering liberal media outlets and civil society groups and punishing free speech with sedition - moves that have drawn international criticism.
